Get the Stockscreener App
0.4439
3.30%
0.0142
Invivyd Inc stock is traded at $0.4439, with a volume of 2.06M.
It is up +3.30% in the last 24 hours and down -42.21% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$0.4297
Open:
$0.42
24h Volume:
2.06M
Relative Volume:
3.35
Market Cap:
$53.10M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.2757
EPS:
-1.61
Net Cash Flow:
$-192.27M
1W Performance:
-18.85%
1M Performance:
-42.21%
6M Performance:
-66.11%
1Y Performance:
-86.96%
1-Day Range:
$0.4043
$0.4528
1-Week Range:
$0.4043
$0.5549
52-Week Range:
$0.4043
$5.195
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.4439 | 53.10M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Charles Schwab Investment Management Inc. Sells 289,312 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 74,764 Shares of Stock - MarketBeat
Invivyd director Terrance McGuire sells shares worth $147,795 By Investing.com - Investing.com South Africa
Invivyd director Terrance McGuire sells shares worth $147,795 - Investing.com
Invivyd, Inc. (NASDAQ:IVVD) Director Sells $30,718.73 in Stock - MarketBeat
Invivyd director Terrance McGuire sells $103,384 in stock - Investing.com
Adagio Therapeutics Stock Hits 52-Week Low at $0.57 Amid Challenges - Investing.com
Fmr LLC Sells 1,046,775 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Fmr LLC Decreases Stock Holdings in Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Invivyd announces board member resignation By Investing.com - Investing.com South Africa
Invivyd announces board member resignation - Investing.com
Analysts Provide An Important Insights On Invivyd Inc (IVVD) - Stocks Register
Invivyd's (IVVD) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
HC Wainwright Cuts Invivyd (NASDAQ:IVVD) Price Target to $10.00 - Defense World
FY2024 Earnings Forecast for Invivyd Issued By HC Wainwright - Defense World
Adagio Therapeutics stock hits 52-week low at $0.72 By Investing.com - Investing.com Australia
Adagio Therapeutics stock hits 52-week low at $0.72 - Investing.com
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates - MSN
Invivyd (NASDAQ:IVVD) Given New $10.00 Price Target at HC Wainwright - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in October - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Q3 2024 Earnings Call Transcript - Insider Monkey
Invivyd Inc (IVVD) Quarterly 10-Q Report - Quartzy
Invivyd’s Q3 2024: Revenue Growth and Strategic Developments - TipRanks
Earnings call: Invivyd reports steady growth amid regulatory challenges - Investing.com
IVVD stock touches 52-week low at $0.81 amid market challenges - Investing.com India
Invivyd earnings missed by $0.18, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor - The Manila Times
Invivyd's PEMGARDA Shows Promise Against COVID Variants Despite Lab Data Dispute | IVVD Stock News - StockTitan
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect - Yahoo Finance
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expe - GuruFocus.com
Invivyd (IVVD) Set to Announce Earnings on Thursday - Defense World
FMR LLC's Strategic Reduction in Invivyd Inc Shares - GuruFocus.com
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Upload - The Manila Times
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term - The Bakersfield Californian
Invivyd's COVID Drug Shows 84% Risk Reduction in Phase 3 Trial, Secures FDA Authorization | IVVD Stock News - StockTitan
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - The Manila Times
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire Inc.
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 - The Manila Times
Invivyd (IVVD) Sets Q3 2024 Earnings Call: Financial Results & Business Updates Coming Nov 14 | IVVD Stock News - StockTitan
EF Hutton Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - MSN
Invivyd (NASDAQ:IVVD) Upgraded at EF Hutton Acquisition Co. I - Defense World
Invivyd (NASDAQ:IVVD) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy" Rating - MarketBeat
Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M - MSN
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Wednesday - Benzinga
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Part - The Manila Times
Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 - Marketscreener.com
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 19 '24 |
Sale |
0.43 |
152,067 |
65,951 |
3,688,079 |
| MCGUIRE TERRANCE | Director |
Dec 17 '24 |
Sale |
0.48 |
97,410 |
46,757 |
3,914,910 |
| MCGUIRE TERRANCE | Director |
Dec 18 '24 |
Sale |
0.47 |
74,764 |
35,087 |
3,840,146 |
| MCGUIRE TERRANCE | Director |
Dec 12 '24 |
Sale |
0.58 |
125,000 |
72,875 |
4,077,679 |
| MCGUIRE TERRANCE | Director |
Dec 16 '24 |
Sale |
0.47 |
65,359 |
30,510 |
4,012,320 |
| MCGUIRE TERRANCE | Director |
Dec 10 '24 |
Sale |
0.59 |
175,000 |
103,005 |
4,363,079 |
| MCGUIRE TERRANCE | Director |
Dec 11 '24 |
Sale |
0.59 |
160,400 |
94,812 |
4,202,679 |
| MCGUIRE TERRANCE | Director |
Dec 09 '24 |
Sale |
0.61 |
150,000 |
91,560 |
4,538,079 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):